

**Radiation Therapy: Dosimetry and Interpreting Therapeutic Margins - Oral Oncology Didactic Lecture Series -**  
**5/17/2024**  
**5/17/2024 4:00:00 PM - 5/17/2024 5:00:00 PM**

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact [ContinuingEducation@mdanderson.org](mailto:ContinuingEducation@mdanderson.org)

**Target Audience:**

Professions: Physician (MD or DO), Dentist, Student or Trainee

**Learning Objectives:**

- 1 Demonstrate effective management of head and neck cancer patients by applying relevant knowledge of anatomy and pathology.
- 1 Describe the various stages involved in prosthetic rehabilitation for head and neck cancer patients, and elucidate their importance in the overall patient care continuum.
- 2 Evaluate and discuss the principles of surgical, radiation therapy, and chemotherapy approaches, and apply them to the comprehensive care of head and neck cancer patients.
- 3 Articulate the key principles underlying major therapies for head and neck cancer and employ strategies for managing primary oral side effects and secondary mucosal complications resulting from cancer therapy.

**Accreditation:**



In support of improving patient care, The University of Texas MD Anderson Cancer Center, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Commercial Support:**

No commercial support has been received for this activity.

**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Richard C Cardoso, DDS	Activity Director	Nothing to disclose - 10/31/2023
Mark S Chambers, DMD MS	Activity Co-Director	Nothing to disclose - 10/23/2023
Clifton D Fuller, MD	Faculty	Grant or research support-

		Elekta   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Siemens Healthineers   Honoraria-Philips (any division)   Grant or research support-Oncospace, Inc (Relationship has ended) - 02/26/2024
Theresa M Hofstede, DDS	Activity Co-Director	Nothing to disclose - 12/28/2023
Marc-Elie Nader, MD	Activity Co-Director	Stocks or stock options, excluding diversified mutual funds-Johnson & Johnson (any division)   Stocks or stock options, excluding diversified mutual funds-Tactile systems technology (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds-Palantir   Stocks or stock options, excluding diversified mutual funds-Artivion (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds-Medtronic, Inc. (any division)   Stocks or stock options, excluding diversified mutual funds-Amgen Inc.   Stocks or stock options, excluding diversified mutual funds-Pfizer Inc. (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds-Nestle   Stocks or stock options, excluding diversified mutual funds-Kimberly-Clark   Stocks or stock options, excluding diversified mutual funds-3M - 04/23/2024